Janssen Announces European Commission Approval of JULUCA ®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals